Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE -110.7%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $98M | $75M | $340M | $73M | $49M | $1.1B | $1.1B | $541M | — | — |
| Enterprise Value | $120M | $97M | $329M | $-59642644 | $179M | $1.1B | $963M | $341M | — | — |
| P/E Ratio → | -0.79 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 15.31 | 11.77 | 149.54 | — | — | — | 30.75 | 18.68 | — | — |
| P/B Ratio | 1.80 | 1.46 | 2.12 | 0.43 | — | 8.72 | 5.91 | 3.23 | — | — |
| P/FCF | — | — | — | — | — | — | — | 16.31 | — | — |
| P/OCF | — | — | — | — | — | — | — | 15.80 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.16 | 144.75 | — | — | — | 26.04 | 11.76 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 10.27 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.0% | 33.0% | 100.0% | — | — | — | 95.7% | 41.9% | — | — |
| Operating Margin | -1366.4% | -1366.4% | -4047.1% | — | — | — | -74.5% | -71.4% | — | — |
| Net Profit Margin | -1834.5% | -1834.5% | -3680.4% | — | — | — | -71.7% | -64.8% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -110.7% | -110.7% | -50.6% | -229.0% | -365.1% | -13.6% | -14.7% | -30.5% | — | — |
| ROA | -69.0% | -69.0% | -37.3% | -55.0% | -44.8% | -9.8% | -10.9% | -14.0% | -59.6% | -102.3% |
| ROIC | -58.8% | -58.8% | -73.9% | -186.5% | -69.2% | -46.3% | -113.9% | — | — | — |
| ROCE | -55.8% | -55.8% | -44.5% | -63.3% | -49.4% | -17.2% | -13.5% | -19.6% | -64.9% | -92.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.85 | 0.85 | 0.28 | 0.20 | — | 0.35 | 0.24 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.42 | -0.07 | -0.78 | — | -0.26 | -0.91 | -1.20 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -6.04 | — | — |
| Interest Coverage | — | — | — | — | -499.98 | — | — | — | -179.83 | -115.30 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.90 | 6.90 | 8.79 | 8.87 | 6.56 | 11.79 | 8.45 | 4.19 | 11.38 | 8.07 |
| Quick Ratio | 6.90 | 6.90 | 8.79 | 8.87 | 6.56 | 11.79 | 8.45 | 4.19 | 11.38 | 8.07 |
| Cash Ratio | 6.30 | 6.30 | 8.43 | 8.53 | 6.42 | 11.44 | 8.27 | 4.12 | 11.18 | 8.06 |
| Asset Turnover | — | 0.06 | 0.01 | — | — | — | 0.14 | 0.13 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 55.33 | 272.58 | — | — | — | 3.36 | 10.15 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 6.1% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $9M | $9M | $2M | $255174 | $4M | $645064 | $616890 | $627085 | $627085 |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KRRO stock.
Korro Bio, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
Korro Bio, Inc.'s return on equity (ROE) is -110.7%. The historical average is -116.3%.
Based on historical data, Korro Bio, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Korro Bio, Inc. has 33.0% gross margin and -1366.4% operating margin.
Key Metrics
Top Statement Risk
Imminent liquidity and dilution
Metrics are mathematically derived from official filings.
Premium Valuation Amidst Clinical Uncertainty
According to current market data, KRRO trades at a P/S ratio of 19.78, a multiple that appears disconnected from the company's pre-commercial status and reliance on sporadic, non-recurring milestone payments rather than a predictable, scalable revenue stream typical of mature biotechnology firms.
The elevated P/S multiple suggests that investors are pricing in significant future success for the OPERA platform rather than current fundamental performance. This valuation warrants caution, as it implies a high growth trajectory that remains unproven in human clinical trials and highly sensitive to binary data readouts.
Persistent Erosion of Invested Capital
Based on reported financial statements, KRRO's ROIC has remained deeply negative, fluctuating between -11.2% and -51.6% over the last ten quarters, which indicates that the company is currently destroying shareholder value as it consumes capital to fund its early-stage research and development pipeline.
The inability to generate positive returns on capital is a structural characteristic of the firm's current R&D-heavy phase. Investors should monitor whether future clinical milestones can eventually drive a pivot toward positive returns, though current trends suggest a continued reliance on external capital to sustain operations.
Working Capital Volatility and Inefficiency
As reported in recent filings, KRRO's asset turnover remains negligible at 0.01, reflecting the company's lack of commercial operations and the inefficiency inherent in a business model that is currently focused entirely on laboratory-based research rather than revenue-generating product sales.
The erratic nature of the company's DSO, which reached 237 days in 2024Q4, highlights the extreme lumpiness of milestone-based revenue recognition. This lack of operational efficiency underscores the difficulty in modeling cash flows for a firm that lacks a recurring revenue base.
Rising Debt Burden Amidst Scarcity
According to quarterly financial records, KRRO's debt-to-equity ratio has deteriorated from 0.20 in 2023Q4 to 0.85 in 2025Q4, signaling an increasing reliance on debt financing even as the company's equity base is systematically eroded by persistent, large-scale operating losses.
The rising leverage ratio is particularly concerning given the absence of EBITDA to cover interest obligations. This trend suggests that the company may be approaching a point where traditional debt financing becomes prohibitively expensive or unavailable, forcing further equity dilution.
Misapplication of P/S Valuation Multiples
Financial analysts frequently misapply the P/S ratio to KRRO, as this metric obscures the reality that the company's revenue is derived from non-recurring collaboration milestones rather than sustainable product sales, leading to a potentially distorted view of the firm's actual commercial viability.
Investors should instead focus on cash runway and the probability-weighted net present value of the clinical pipeline. Using P/S as a primary valuation tool for a pre-revenue biotech firm risks ignoring the binary nature of clinical outcomes and the high probability of future equity dilution.